Sökning: onr:"swepub:oai:gup.ub.gu.se/318901" > COVID-19 clinical o...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 08507naa a2200853 4500 | |
001 | oai:gup.ub.gu.se/318901 | |
003 | SwePub | |
008 | 240528s2022 | |||||||||||000 ||eng| | |
009 | oai:DiVA.org:oru-100745 | |
009 | oai:DiVA.org:umu-199108 | |
009 | oai:DiVA.org:liu-187856 | |
009 | oai:DiVA.org:uu-495215 | |
009 | oai:lup.lub.lu.se:24ebd2ae-c532-4a55-b5b0-a6052d555472 | |
009 | oai:prod.swepub.kib.ki.se:150531437 | |
024 | 7 | a https://gup.ub.gu.se/publication/3189012 URI |
024 | 7 | a https://doi.org/10.1002/acn3.516462 DOI |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-1007452 URI |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-1991082 URI |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-1878562 URI |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-4952152 URI |
024 | 7 | a https://lup.lub.lu.se/record/24ebd2ae-c532-4a55-b5b0-a6052d5554722 URI |
024 | 7 | a http://kipublications.ki.se/Default.aspx?queryparsed=id:1505314372 URI |
040 | a (SwePub)gud (SwePub)orud (SwePub)umud (SwePub)liud (SwePub)uud (SwePub)lud (SwePub)ki | |
041 | a eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Longinetti, E.u Karolinska Institutet,Karolinska Institute4 aut |
245 | 1 0 | a COVID-19 clinical outcomes and DMT of MS patients and population-based controls |
264 | c 2022-08-22 | |
264 | 1 | b Wiley,c 2022 |
500 | a Funding Agencies|Patient-Centered Outcomes Research Institute (PCORI) Award [MS-1511-33196]; Swedish MRC [2020-02700]; Swedish Research Council [2021-01418]; Swedish Research Council for Health, Working Life, and Welfare [2020-0115]; Knut and Alice Wallenbergs foundation [KAW 2020.0299_VC-2020-0040/VC-2021-0018] | |
520 | a Objective: To estimate risks for all-cause mortality and for severe COVID-19 in multiple sclerosis patients and across relapsing-remitting multiple sclerosis patients exposed to disease-modifying therapies. Methods: We conducted a Swedish nationwide population-based multi-register linkage cohort study and followed all multiple sclerosis patients (n = 17,692 in March 2020), individually age-, sex-, and region-matched to five population-based controls (n = 86,176 in March 2020) during March 2020-June 2021. We compared annual all-cause mortality within and across cohorts, and assessed incidence rates and relative risks for hospitalization, intensive care admission, and death due to COVID-19 in relation to disease-modifying therapy use, using Cox regression. Results: Absolute all-cause mortality among multiple sclerosis patients was higher from March to December 2020 than in previous years, but relative risks versus the population-based controls were similar to preceding years. Incidence rates of hospitalization, intensive care admission, and death due to COVID-19 remained in line with those for all-cause hospitalization, intensive care admission, and mortality. Among relapsing-remitting patients on rituximab, trends for differences in risk of hospitalization due to COVID-19 remained in the demographics-, socioeconomic status-, comorbidity-, and multiple sclerosis severity-adjusted model. Interpretation: Risks of severe COVID-19-related outcomes were increased among multiple sclerosis patients as a whole compared to population controls, but risk increases were also seen for non-COVID-19 hospitalization, intensive care admission, and mortality, and did not significantly differ during the pandemic compared to pre-pandemic years. The risk conveyed by disease-modifying therapies was smaller than previously assumed, likely as a consequence of the possibility to better control for confounders. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Medicinska och farmaceutiska grundvetenskaperx Neurovetenskaper0 (SwePub)301052 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Basic Medicinex Neurosciences0 (SwePub)301052 hsv//eng |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Hälsovetenskapx Folkhälsovetenskap, global hälsa, socialmedicin och epidemiologi0 (SwePub)303022 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Health Sciencesx Public Health, Global Health, Social Medicine and Epidemiology0 (SwePub)303022 hsv//eng |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Neurologi0 (SwePub)302072 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Neurology0 (SwePub)302072 hsv//eng |
653 | a multiple-sclerosis | |
653 | a register | |
653 | a Neurosciences & Neurology | |
700 | 1 | a Bower, H.u Karolinska Institutet,Karolinska Institute4 aut |
700 | 1 | a McKay, K. A.u Karolinska Institutet,Karolinska Institute4 aut |
700 | 1 | a Englund, S.u Karolinska Institutet,Karolinska Institute4 aut |
700 | 1 | a Burman, Joachim,d 1974-u Uppsala University,Uppsala universitet,Institutionen för medicinska vetenskaper,Experimentell neurologi4 aut0 (Swepub:uu)joabu293 |
700 | 1 | a Fink, K.u Karolinska Institutet,Karolinska Institute4 aut |
700 | 1 | a Fogdell-Hahn, A.u Karolinska Institutet,Karolinska Institute4 aut |
700 | 1 | a Gunnarsson, Martin,d 1973-u Örebro University,Örebro universitet,Institutionen för medicinska vetenskaper,Region Örebro län,Department of Neurology, Örebro University, Örebro, Sweden,Örebro Univ, Dept Neurol, Örebro, Sweden.4 aut0 (Swepub:oru)mign |
700 | 1 | a Hillert, J.u Karolinska Institutet,Karolinska Institute4 aut |
700 | 1 | a Langer-Gould, A.u Clinical and Translational Neuroscience, Southern California Permanente Medical Group, Kaiser Permanente, Los Angeles, USA,Clinical and Translational Neuroscience, Southern California Permanente Medical Group, Kaiser Permanente, Los Angeles, United States,Kaiser Permanente, Clin & Translat Neurosci, Southern Calif Permanente Med Grp, Los Angeles, CA USA.4 aut |
700 | 1 | a Lycke, Jan,d 1956u University of Gothenburg,Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi, sektionen för klinisk neurovetenskap,Institute of Neuroscience and Physiology, Department of Clinical Neuroscience,Department of Clinical Neuroscience, University of Gothenburg, Gothenburg, Sweden,Univ Gothenburg, Dept Clin Neurosci, Gothenburg, Sweden.4 aut0 (Swepub:gu)xlycja |
700 | 1 | a Nilsson, Petrau Lund University,Lunds universitet,Neurologi, Lund,Sektion IV,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Neurology, Lund,Section IV,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)neur-pn8 |
700 | 1 | a Salzer, Jonatanu Umeå University,Umeå universitet,Neurovetenskaper,Umeå Univ, Dept Clin Sci, Neurosci, Umeå, Sweden.4 aut0 (Swepub:umu)jonser01 |
700 | 1 | a Svenningsson, A.u Karolinska Institutet4 aut |
700 | 1 | a Mellergård, Johanu Linköping University,Linköpings universitet,Avdelningen för neurobiologi,Medicinska fakulteten,Region Östergötland, Neurologiska kliniken i Linköping,Linköping Univ, Dept Biomed & Clin Sci, Linköping, Sweden.4 aut0 (Swepub:liu)johme15 |
700 | 1 | a Olsson, T.u Karolinska Institutet,Karolinska Institute4 aut |
700 | 1 | a Piehl, F.u Karolinska Institute4 aut |
700 | 1 | a Frisell, T.u Karolinska Institutet,Karolinska Institute4 aut |
710 | 2 | a Karolinska Institutetb Karolinska Institute4 org |
773 | 0 | t Annals of Clinical and Translational Neurologyd : Wileyg 9:9, s. 1449-1458q 9:9<1449-1458x 2328-9503 |
856 | 4 | u https://doi.org/10.1002/acn3.51646y Fulltext |
856 | 4 | u https://umu.diva-portal.org/smash/get/diva2:1701633/FULLTEXT01.pdfx primaryx Raw objecty fulltext:print |
856 | 4 | u https://liu.diva-portal.org/smash/get/diva2:1691656/FULLTEXT01.pdfx primaryx Raw objecty fulltext:print |
856 | 4 | u https://uu.diva-portal.org/smash/get/diva2:1730884/FULLTEXT01.pdfx primaryx Raw objecty fulltext:print |
856 | 4 | u http://dx.doi.org/10.1002/acn3.51646x freey FULLTEXT |
856 | 4 8 | u https://gup.ub.gu.se/publication/318901 |
856 | 4 8 | u https://doi.org/10.1002/acn3.51646 |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-100745 |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-199108 |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-187856 |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-495215 |
856 | 4 8 | u https://lup.lub.lu.se/record/24ebd2ae-c532-4a55-b5b0-a6052d555472 |
856 | 4 8 | u http://kipublications.ki.se/Default.aspx?queryparsed=id:150531437 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.